Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
6 stopped studies mapped to B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities and descendants · 100% state a reason
Over the 6 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With… | Phase 1 / Phase 2 | terminated | Aug 6, 2020 | Takeda | Phase 1 enrollment was terminated due to dose-limiting toxicities, thus the study was terminated by… | Safety / toxicity |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Study was closed early due to low accrual and lack of response. | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia… | Phase 1 | terminated | Jun 30, 2016 | Northwestern University | Due to funding and accrual issues | Enrollment / accrual |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic… | Phase 2 | terminated | May 2, 2014 | National Cancer Institute (NCI) | Slow accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 2, 2025source: clinicaltrials